Centessa Pharmaceuticals plc - ADR

NASDAQ:CNTA   1:00:00 PM EDT
4.05
+0.06 (+1.50%)
1:48:43 PM EDT: $4.00 -0.05 (-1.24%)
Earnings Announcements

Centessa Pharmaceuticals Reports Q3 Financial Results

Published: 11/10/2022 12:53 GMT
Centessa Pharmaceuticals plc - ADR (CNTA) - Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022.
Centessa Pharmaceuticals Plc - Qtrly Cash and Cash Equivalents of $444.8 Million.
Centessa Pharmaceuticals Plc - Cash Runway Into 2026 Enables Multiple Clinical Readouts Across Pipeline.
Centessa Pharmaceuticals Plc - Ind Submission for Lb101, a Conditionally Tetravalent Pd-l1xcd47 Bispecific Monoclonal Antibody, on Track for Late 2022.
Centessa Pharmaceuticals Plc - Qtrly Loss per Share $0.57.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.51

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.48

More details on our Analysts Page.